130 related articles for article (PubMed ID: 38483395)
1. Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma-Reply.
Qin S
JAMA Oncol; 2024 May; 10(5):674-675. PubMed ID: 38483395
[No Abstract] [Full Text] [Related]
2. Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma.
Sun R; Moraleda JM; Wei LJ
JAMA Oncol; 2024 May; 10(5):674. PubMed ID: 38483380
[No Abstract] [Full Text] [Related]
3. Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis.
Zheng Z; Lin Y; Cai H
Front Public Health; 2024; 12():1356244. PubMed ID: 38562257
[TBL] [Abstract][Full Text] [Related]
4. Rupture of a Small Hepatocellular Carcinoma in a Stable Disease State in a Patient Receiving Sorafenib Treatment.
Tsuboi R; Asano T; Matsuura K; Asabe S; Mashima H
Chin Med J (Engl); 2018 Apr; 131(8):999-1000. PubMed ID: 29664064
[No Abstract] [Full Text] [Related]
5. RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.
Qin S; Finn RS; Kudo M; Meyer T; Vogel A; Ducreux M; Macarulla TM; Tomasello G; Boisserie F; Hou J; Li X; Song J; Zhu AX
Future Oncol; 2019 Jun; 15(16):1811-1822. PubMed ID: 30969136
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
Su D; Wu B; Shi L
JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
[TBL] [Abstract][Full Text] [Related]
7. AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma.
Altayar O; Shah R; Chang CY; Falck-Ytter Y; Muir AJ
Gastroenterology; 2022 Mar; 162(3):937-951. PubMed ID: 35210015
[No Abstract] [Full Text] [Related]
8. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
9. Review article: systemic treatment of hepatocellular carcinoma.
Pinter M; Peck-Radosavljevic M
Aliment Pharmacol Ther; 2018 Sep; 48(6):598-609. PubMed ID: 30039640
[TBL] [Abstract][Full Text] [Related]
10. Comments on Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: Reply.
Yim HJ; Ahn YE; Kim TH; Jung YK
Gut Liver; 2023 Mar; 17(2):341-342. PubMed ID: 36789579
[No Abstract] [Full Text] [Related]
11. Efficacy of Ramucirumab
Maesaka K; Sakamori R; Yamada R; Tahata Y; Ohkawa K; Oshita M; Tamura S; Hagiwara H; Mita E; Yakushijin T; Inada M; Kodama T; Hikita H; Tatsumi T; Takehara T
Anticancer Res; 2021 Apr; 41(4):2187-2192. PubMed ID: 33813432
[TBL] [Abstract][Full Text] [Related]
12. The synergistic effect of sorafenib and TNF-α inhibitor on hepatocellular carcinoma.
Wang M; Wu M; Yang T
EBioMedicine; 2019 Feb; 40():11-12. PubMed ID: 30651221
[No Abstract] [Full Text] [Related]
13. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
14. Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
Hou Y; Wu B
Cancer Commun (Lond); 2020 Dec; 40(12):743-745. PubMed ID: 33159490
[No Abstract] [Full Text] [Related]
15. Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma.
Chen Q; Sun Q; Zhang J; Li B; Feng Q; Liu J
PLoS One; 2024; 19(3):e0295090. PubMed ID: 38437209
[TBL] [Abstract][Full Text] [Related]
16. Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report.
Chen SC; Chao Y; Yang MH
Am J Gastroenterol; 2017 Apr; 112(4):659-660. PubMed ID: 28381841
[No Abstract] [Full Text] [Related]
17. [New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma].
Minot-This MS; Edeline J
Bull Cancer; 2021 Feb; 108(2):139-140. PubMed ID: 33546873
[No Abstract] [Full Text] [Related]
18. Sorafenib for Recurrent Hepatocellular Carcinoma after Liver Transplantation.
Kim BH; Park JW
J Korean Med Sci; 2018 Nov; 33(45):e286. PubMed ID: 30402051
[No Abstract] [Full Text] [Related]
19. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R
Cancer Med; 2020 Jul; 9(13):4640-4647. PubMed ID: 32378799
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.
Cheng AL; Kang YK; He AR; Lim HY; Ryoo BY; Hung CH; Sheen IS; Izumi N; Austin T; Wang Q; Greenberg J; Shiratori S; Beckman RA; Kudo M;
J Hepatol; 2015 Oct; 63(4):896-904. PubMed ID: 26071796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]